Vor Biopharma: Matthew Patterson
Vor Biopharma - an oncology company based in Cambridge, Massachusetts which is pioneering engineered haematopoietic stem cells (eHSCs) for the treatment of cancer - has appointed Matthew R Patterson to its Board of Directors.
Patterson has nearly 30 years of experience in research, development, and commercialisation of innovative treatments: and has held senior leadership positions in both private and publicly-traded biotechnology companies.
He is the co-founder of Audentes Therapeutics and was its CEO for eight years until its acquisition by Astellas Pharma in 2020. He also chaired the company’s Board of Directors and continues to serve as a strategic advisor. Prior to Audentes, Mr Patterson was an entrepreneur-in-residence with OrbiMed. Earlier in his career, he worked for Genzyme Corporation, BioMarin Pharmaceutical, and Amicus Therapeutics. He received his bachelor’s degree in biochemistry from Bowdoin College.
Patterson is also a member of the Board of Directors of Homology Medicines, Inc., and the Board of Directors of 5:01 Acquisition Corp.
He currently serves as the Chairman of the Alliance for Regenerative Medicine (ARM), the international advocacy organisation representing the gene and cell therapy and broader regenerative medicine sector.
Vor Biopharma is a founded entity of PureTech Health.
